Olympus Unveils Strategy to Transform Endoscopy Care Through AI, Robotics, and Organizational Restructuring

Olympus Corporation unveiled a comprehensive strategy to transform endoscopy-enabled care through innovation and operational excellence. The global MedTech company aims to accelerate cutting-edge technologies and reinforce its leadership position while improving outcomes for millions of patients worldwide. According to Bob White, Representative Executive Officer, President and Chief Executive Officer at Olympus, the company is building on its industry-leading installed base of endoscopy systems to move beyond hardware toward a future defined by intelligent, integrated care.

The strategy envisions a future where advanced, minimally invasive endoscopy powered by AI, robotics, and connected digital ecosystems enables earlier detection, improves clinical outcomes, enhances patient safety, and ensures continuity of care. With the world's largest installed base of endoscopy systems and significant unmet clinical needs across the care pathway, Olympus believes it is uniquely positioned to scale innovation globally and redefine standards in endoscopy-enabled care. The company's approach is built on three strategic pillars: Innovation-driven Growth, Simplicity, and Accountability.

Innovation-driven Growth will focus on expanding leadership in AI-powered endoscopy, robotics and cloud-connected solutions. Simplicity and Accountability will serve as operational accelerators, streamlining processes, empowering teams, and driving sustainable performance. As part of this transformation, Olympus will implement a global organizational restructuring expected to yield approximately 24 billion yen in run rate savings and a net reduction of roughly 2,000 positions in the global workforce. The optimization will simplify organizational layers and expand managerial spans of control to foster agility and clearer accountability.

The integrated growth and transformation plan is designed to deliver sustained value for patients, healthcare providers, and shareholders. The company targets 5% year-on-year revenue growth by fiscal year 2029, annual 100 basis-point growth from fiscal year 2026, more than 10% EPS Compound Annual Growth Rate, and continuous improvement in free cash flow. Capital will be deployed dynamically to support innovation, dividends, share buybacks, and strategic mergers and acquisitions. For more information about the company's broader initiatives, visit https://www.olympus-global.com.

Olympus also announced several leadership transitions effective in 2026. Keith Boettiger, currently Corporate Officer and Co-head of the Gastrointestinal Solutions Division, will be appointed Executive Officer and Gastrointestinal Solutions Division Head effective April 1, 2026. He will succeed Frank Drewalowski, who will transition to Senior Advisor to the Chief Executive Officer. Yasuo Takeuchi will step down as Representative Executive Officer, Executive Chairperson and ESG Officer at the end of March 2026, concluding over four decades of service. Takeuchi led Olympus' transformation into a pure-play MedTech company and cultivated its global Purpose and Core Values during his tenure as President and CEO beginning in 2019.